CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in patients with cystic fibrosis (“CF”) at European Respiratory Society (ERS) International Congress 2023, which is being held September 9-13, 2023, in Milan, Italy. The abstract was submitted as a Late-Breaking Abstract and selected for oral presentation at the conference.

The Phase 1b/2a data for BX004 will also be available as an e-poster on the virtual congress platform.

Details of the oral presentation are as follows:

Title: A novel treatment for chronic P. aeruginosa pulmonary infection in CF subjects - A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study to evaluate phage therapy

Abstract: OA1534
Session #180: “Cystic fibrosis in adults”
Date and Time: Sunday, September 10, 2023, 15:45-17:00 CEST (1^st talk in session, 15:45-15:50 CEST)
Location: Brown 3
Presenter: Urania Rappo, MD, BiomX Inc., Cambridge, United States

The poster will also be made available on the publications section of the BiomX website on September 10, 2023.

About BX004

BiomX is developing BX004, utilizing its proprietary BOLT platform, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. In September 2021, BX004 was cleared by the U.S. Food and Drug Administration to initiate a Phase 1b/2a study in CF patients with chronic pulmonary infections caused by P. aeruginosa. BX004 is being developed for the treatment of chronic respiratory infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. The Phase 1b/2a trial is composed of two parts. Part 1 of the study evaluated the safety, pharmacokinetics, and microbiologic/clinical activity of BX004 in nine CF patients in a single ascending dose and multiple dose design. Part 2 of the study will evaluate the safety and efficacy of BX004 in at least 24 CF patients randomized to a treatment or placebo cohort in a 2:1 ratio. Results from Part 2 of the trial are expected in November 2023.

About BiomX

BiomX is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

Safe Harbor

This press release contains express or implied “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. For example, when BiomX discusses the potential safety or efficacy of BX004, and the expected timing, design and patient enrollment of Part 2 of the Phase 1b/2a study, BiomX is making forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption “Risk Factors” in BiomX’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2023 and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Forward-looking statements are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking to update forward-looking statements.

BiomX Contacts:

Investor Relations:
LifeSci Advisors, LLC
John Mullaly
(617)-698-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.

BiomX, Inc.
Anat Primovich
Corporate Project Manager
+972 (50) 697-7228
This email address is being protected from spambots. You need JavaScript enabled to view it.